American Century Companies Inc. lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 138.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 239,386 shares of the biopharmaceutical company’s stock after purchasing an additional 139,179 shares during the quarter. American Century Companies Inc. owned about 0.13% of Amicus Therapeutics worth $3,600,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB purchased a new stake in shares of Amicus Therapeutics during the fourth quarter worth approximately $219,000. Rockefeller Financial Services Inc. purchased a new position in Amicus Therapeutics in the fourth quarter worth $276,000. Virtus Fund Advisers LLC purchased a new position in Amicus Therapeutics in the fourth quarter worth $392,000. Adams Diversified Equity Fund Inc. purchased a new position in Amicus Therapeutics in the fourth quarter worth $502,000. Finally, Teacher Retirement System of Texas raised its position in Amicus Therapeutics by 314.5% in the fourth quarter. Teacher Retirement System of Texas now owns 49,939 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 37,891 shares in the last quarter.
Amicus Therapeutics opened at $15.79 on Friday, Marketbeat Ratings reports. The company has a current ratio of 4.21, a quick ratio of 4.15 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of -5.41 and a beta of 1.48. Amicus Therapeutics, Inc. has a fifty-two week low of $7.46 and a fifty-two week high of $17.40.
Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.08. The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $16.78 million. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. equities analysts predict that Amicus Therapeutics, Inc. will post -1.26 EPS for the current year.
Several research firms have issued reports on FOLD. BidaskClub upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 19th. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Leerink Swann increased their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Finally, Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. Two analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.06.
In other Amicus Therapeutics news, Director Michael Raab sold 5,000 shares of the company’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $14.41, for a total value of $72,050.00. Following the sale, the director now owns 10,814 shares of the company’s stock, valued at $155,829.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Margaret G. Mcglynn sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $16.00, for a total value of $160,000.00. Following the completion of the sale, the director now directly owns 25,814 shares in the company, valued at approximately $413,024. The disclosure for this sale can be found here. Insiders sold 136,899 shares of company stock worth $2,035,875 in the last three months. 2.90% of the stock is owned by corporate insiders.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.